Fluorodeoxyglucose-PET in the management of breast cancer

Radiologic Clinics of North America

Volumn 42, Issue 6, 2004, Pages 1113-1122

  Kumar, Rakesh ^a   Alavi, Abass ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CA 15-3 ANTIGEN; FLUORINE 18; FLUORODEOXYGLUCOSE F 18; KI 67 ANTIGEN; METHOXY ISOBUTYL ISONITRILE TECHNETIUM TC 99M; TETROFOSMIN TC 99M;

ADJUVANT CHEMOTHERAPY; ARTICLE; BONE MARROW METASTASIS; BONE SCINTISCANNING; BREAST CANCER; CANCER DIAGNOSIS; CANCER RECURRENCE; CANCER REGRESSION; CANCER STAGING; DIAGNOSTIC ACCURACY; EARLY DIAGNOSIS; ECHOGRAPHY; GLUCOSE METABOLISM; HISTOPATHOLOGY; HUMAN; IMMUNOHISTOCHEMISTRY; LYMPH NODE METASTASIS; MALIGNANT NEOPLASTIC DISEASE; MAMMOGRAPHY; METASTASIS; NUCLEAR MAGNETIC RESONANCE IMAGING; PHYSICAL EXAMINATION; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROGNOSIS; SCINTIMAMMOGRAPHY; SENSITIVITY ANALYSIS; SENSITIVITY AND SPECIFICITY; SENTINEL LYMPH NODE BIOPSY; TREATMENT OUTCOME; TUMOR VOLUME; WHOLE BODY SCINTISCANNING;

EID: 5444234387     PISSN: 00338389     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.rcl.2004.08.005     Document Type: Review

References (76)

1. S.H. Landis, T. Murray, S. Bolden, and P.A. Wingo Cancer statistics, 1999 CA Cancer J Clin 49 1 1999 8 31
2. P.A. Wingo, C.J. Cardinez, S.H. Landis, R.T. Greenlee, L.A. Ries, and R.N. Anderson Long-term trends in cancer mortality in the United States, 1930-1998 Cancer 97 12 Suppl 2003 3133 3175
3. K. Kerlikowske, D. Grady, J. Barclay, E.A. Sickles, A. Eaton, and V. Ernster Positive predictive value of screening mammography by age and family history of breast cancer JAMA 270 20 1993 2444 2450
4. L.M. Foxcroft, E.B. Evans, H.K. Joshua, and C. Hirst Breast cancers invisible on mammography Aust N Z J Surg 70 3 2000 162 167
5. T.M. Kolb, J. Lichy, and J.H. Newhouse Comparison of the performance of screening mammography, physical examination, and breast US and evaluation of factors that influence them: an analysis of 27,825 patient evaluations Radiology 225 1 2002 165 175
6. M. Morrow Magnetic resonance imaging in the preoperative evaluation of breast cancer: primum non nocere J Am Coll Surg 198 2 2004 240 241
7. M. Liberman, F. Sampalis, D.S. Mulder, and J.S. Sampalis Breast cancer diagnosis by scintimammography: a meta-analysis and review of the literature Breast Cancer Res Treat 80 1 2003 115 126
8. H. Minn, and I. Soini [18F]fluorodeoxyglucose scintigraphy in diagnosis and follow up of treatment in advanced breast cancer Eur J Nucl Med 15 2 1989 61 66
9. R.L. Wahl, R.L. Cody, G.D. Hutchins, and E.E. Mudgett Primary and metastatic breast carcinoma: initial clinical evaluation with PET with the radiolabeled glucose analogue 2-[F-18]-fluoro-2-deoxy-D-glucose Radiology 179 3 1991 765 770
10. K. Kubota, T. Matsuzawa, A. Amemiya, M. Kondo, T. Fujiwara, and S. Watanuki Imaging of breast cancer with [18F]fluorodeoxyglucose and positron emission tomography J Comput Assist Tomogr 13 6 1989 1097 1098
11. C.K. Hoh, R.A. Hawkins, J.A. Glaspy, M. Dahlbom, N.Y. Tse, and E.J. Hoffman Cancer detection with whole-body PET using 2-[18F]fluoro-2-deoxy-D- glucose J Comput Assist Tomogr 17 1 1993 582 589
12. O.E. Nieweg, E.E. Kim, W.H. Wong, W.F. Broussard, S.E. Singletary, and G.N. Hortobagyi Positron emission tomography with fluorine-18-deoxyglucose in the detection and staging of breast cancer Cancer 71 12 1993 3920 3925
13. L.P. Adler, J.P. Crowe, N.K. al-Kaisi, and J.L. Sunshine Evaluation of breast masses and axillary lymph nodes with [F-18] 2-deoxy-2-fluoro-D-glucose PET Radiology 187 3 1993 743 750
14. F. Dehdashti, J.E. Mortimer, B.A. Siegel, L.K. Griffeth, T.J. Bonasera, and M.J. Fusselman Positron tomographic assessment of estrogen receptors in breast cancer: comparison with FDG-PET and in vitro receptor assays J Nucl Med 36 10 1995 1766 1774
15. N. Avril, J. Dose, F. Janicke, S. Bense, S. Ziegler, and C. Laubenbacher Metabolic characterization of breast tumors with positron emission tomography using F-18 fluorodeoxyglucose J Clin Oncol 14 6 1996 1848 1857
16. 18F-FDG PET: histologic and immunohistochemical tissue analysis J Nucl Med 42 1 2001 9 16
17. H. Schirrmeister, T. Kuhn, A. Guhlmann, C. Santjohanser, T. Horster, and K. Nussle Fluorine-18 2-deoxy-2-fluoro-D-glucose PET in the preoperative staging of breast cancer: comparison with the standard staging procedures Eur J Nucl Med 28 3 2001 351 358
18. C. Walter, K. Scheidhauer, A. Scharl, U.J. Goering, P. Theissen, and H. Kugel Clinical and diagnostic value of preoperative MR mammography and FDG-PET in suspicious breast lesions Eur Radiol 13 7 2003 1651 1656
19. M. Heinisch, H.J. Gallowitsch, P. Mikosch, E. Kresnik, G. Kumnig, and I. Gomez Comparison of FDG-PET and dynamic contrast-enhanced MRI in the evaluation of suggestive breast lesions Breast 12 1 2003 17 22
20. N. Avril, C.A. Rose, M. Schelling, J. Dose, W. Kuhn, and S. Bense Breast imaging with positron emission tomography and fluorine-18 fluorodeoxyglucose: use and limitations J Clin Oncol 18 20 2000 3495 3502
21. F. Crippa, R. Agresti, E. Seregni, M. Greco, C. Pascali, and A. Bogni Prospective evaluation of fluorine-18-FDG PET in presurgical staging of axilla in breast cancer J Nucl Med 39 1 1998 4 9
22. A. Buck, H. Schirrmeister, T. Kuhn, C. Shen, T. Kalker, and J. Kotzerke FDG uptake in breast cancer: correlation with biological and clinical prognostic parameters Eur J Nucl Med Mol Imaging 29 10 2002 1317 1323
23. E.J. Hoffman, S.C. Huang, and M.E. Phelps Quantitation in positron emission computed tomography: 1. Effect of object size J Comput Assist Tomogr 3 3 1979 299 308
24. R. Kumar, S. Mitchell, and A. Alavi F18-FDG Uptake and breast density in women with normal breast tissue J Nucl Med 45 8 2004 1423 1424
25. J.J. Albertini, G.H. Lyman, C. Cox, T. Yeatman, L. Balducci, and N. Ku Lymphatic mapping and sentinel node biopsy in the patient with breast cancer JAMA 276 22 1996 1818 1822
26. R. Kumar, S. Jana, S.I. Heiba, M. Dakhel, D. Axelrod, and B. Siegel Retrospective analysis of sentinel node localization in multicentric palpable and non-palpable breast cancer J Nucl Med 44 1 2003 7 10
27. C.H. Kao, J.F. Hsieh, S.C. Tsai, Y.J. Ho, and R.F. Yen Comparison and discrepancy of 18F-2-deoxyglucose positron emission tomography and Tc-99m MDP bone scan to detect bone metastases Anticancer Res 20 3B 2000 2189 2192
28. L. Kostakoglu, and S.J. Goldsmith 18F-FDG PET evaluation of the response to therapy for lymphoma and for breast, lung, and colorectal carcinoma J Nucl Med 44 2 2003 224 239
29. W.B. Eubank, D.A. Mankoff, H.J. Vesselle, J.F. Eary, E.K. Schubert, and L.K. Dunnwald Detection of locoregional and distant recurrences in breast cancer patients by using FDG PET Radiographics 22 1 2002 5 17
30. E. Barranger, D. Grahek, M. Antoine, F. Montravers, J.N. Talbot, and S. Uzan Evaluation of fluorodeoxyglucose positron emission tomography in the detection of axillary lymph node metastases in patients with early-stage breast cancer Ann Surg Oncol 10 6 2003 622 627
31. M. Greco, F. Crippa, R. Agresti, E. Seregni, A. Gerali, and R. Giovanazzi Axillary lymph node staging in breast cancer by 2-fluoro-2-deoxy-D-glucose- positron emission tomography: clinical evaluation and alternative management J Natl Cancer Inst 93 8 2001 630 635
32. C.I. Utech, C.S. Young, and P.F. Winter Prospective evaluation of fluorine-18 fluorodeoxyglucose positron emission tomography in breast cancer for staging of the axilla related to surgery and immunocytochemistry Eur J Nucl Med 23 12 1996 1588 1593
33. J.J. van der Hoeven, O.S. Hoekstra, E.F. Comans, R. Pijpers, R.P. Boom, and D. van Geldere Determinants of diagnostic performance of [F-18]fluorodeoxyglucose positron emission tomography for axillary staging in breast cancer Ann Surg 236 5 2002 619 624
34. G. Zornoza, M.J. Garcia-Velloso, J. Sola, F.M. Regueira, L. Pina, and C. Beorlegui 18F-FDG PET complemented with sentinel lymph node biopsy in the detection of axillary involvement in breast cancer Eur J Surg Oncol 30 1 2004 15 19
35. K. Yutani, M. Tatsumi, E. Shiba, H. Kusuoka, and T. Nishimura Comparison of dual-head coincidence gamma camera FDG imaging with FDG PET in detection of breast cancer and axillary lymph node metastasis J Nucl Med 40 6 1999 1003 1008
36. L.P. Adler, P.F. Faulhaber, K.C. Schnur, N.L. Al-Kasi, and R.R. Shenk Axillary lymph node metastases: screening with [F-18]2-deoxy-2-fluoro-D-glucose (FDG) PET Radiology 203 2 1997 323 327
37. J.P. Crowe Jr, L.P. Adler, R.R. Shenk, and J. Sunshine Positron emission tomography and breast masses: comparison with clinical, mammographic, and pathological findings Ann Surg Oncol 1 2 1994 132 140
38. D.Y. Noh, I.J. Yun, J.S. Kim, H.S. Kang, D.S. Lee, and J.K. Chung Diagnostic value of positron emission tomography for detecting breast cancer World J Surg 22 3 1998 223 227
39. I.C. Smith, K.N. Ogston, P. Whitford, F.W. Smith, P. Sharp, and M. Norton Staging of the axilla in breast cancer: accurate in vivo assessment using positron emission tomography with 2-(fluorine-18)-fluoro-2-deoxy-D-glucose Ann Surg 228 2 1998 220 227
40. K. Scheidhauer, A. Scharl, U. Pietrzyk, R. Wagner, U.J. Gohring, and K. Schomacker Qualitative [18F]FDG positron emission tomography in primary breast cancer: clinical relevance and practicability Eur J Nucl Med 23 6 1996 618 623
41. U. Guller, E.U. Nitzsche, U. Schirp, C.T. Viehl, J. Torhorst, and H. Moch Selective axillary surgery in breast cancer patients based on positron emission tomography with 18F-fluoro-2-deoxy-D-glucose: not yet! Breast Cancer Res Treat 71 2 2002 171 173
42. N. Avril, J. Dose, F. Janicke, S. Ziegler, W. Romer, and W. Weber Assessment of axillary lymph node involvement in breast cancer patients with positron emission tomography using radiolabeled 2-(fluorine-18)-fluoro-2-deoxy- D-glucose J Natl Cancer Inst 88 17 1996 1204 1209
43. P.R. Kelemen, V. Lowe, and N. Phillips Positron emission tomography and sentinel lymph node dissection in breast cancer Clin Breast Cancer 3 1 2002 73 77
44. M.K. Fehr, R. Hornung, Z. Varga, D. Burger, T. Hess, and U. Haller Axillary staging using positron emission tomography in breast cancer patients qualifying for sentinel lymph node biopsy Breast J 10 2 2004 89 93
45. H. Schirrmeister, T. Kuhn, A. Guhlmann, C. Santjohanser, T. Horster, and K. Nussle Fluorine-18 2-deoxy-2-fluoro-D-glucose PET in the preoperative staging of breast cancer: comparison with the standard staging procedures Eur J Nucl Med 28 3 2001 351 358
46. P. Freneaux, C. Nos, A. Vincent-Salomon, P. Genin, B. Sigal-Zafrani, and A. Al Ghuzlan Histological detection of minimal metastatic involvement in axillary sentinel nodes: a rational basis for a sensitive methodology usable in daily practice Mod Pathol 15 6 2002 641 646
47. R. Kumar, S. Potenta, V.A. Loving, H.M. Zhuang, S. Orel, and M. Schnall FDG-PET positive lymph nodes are highly predictive of metastasis in breast cancer [abstract] J Nucl Med 45 Suppl 2004 154
48. R.L. Wahl, B.A. Siegel, R.E. Coleman, and C.G. Gatsonis Prospective multicenter study of axillary nodal staging by positron emission tomography in breast cancer: a report of the staging breast cancer with PET Study Group J Clin Oncol 22 2 2004 277 285
49. D.H. Moon, J. Maddahi, D.H. Silverman, J.A. Glaspy, M.E. Phelps, and C.K. Hoh Accuracy of whole-body fluorine-18-FDG PET for the detection of recurrent or metastatic breast carcinoma J Nucl Med 39 3 1998 431 435
50. H.J. Gallowitsch, E. Kresnik, J. Gasser, G. Kumnig, I. Igerc, and P. Mikosch F-18 fluorodeoxyglucose positron-emission tomography in the diagnosis of tumor recurrence and metastases in the follow-up of patients with breast carcinoma: a comparison to conventional imaging Invest Radiol 38 5 2003 250 256
51. H. Schirrmeister, A. Guhlmann, J. Kotzerke, C. Santjohanser, T. Kuhn, and R. Kreienberg Early detection and accurate description of extent of metastatic bone disease in breast cancer with fluoride ion and positron emission tomography J Clin Oncol 17 8 1999 2381 2389
52. P.B. Hathaway, D.A. Mankoff, K.R. Maravilla, M.M. Austin-Seymour, G.K. Ellis, and J.R. Gralow Value of combined FDG PET and MR imaging in the evaluation of suspected recurrent local-regional breast cancer: preliminary experience Radiology 210 3 1999 807 814
53. A. Ahmad, S. Barrington, M. Maisey, and R.D. Rubens Use of positron emission tomography in evaluation of brachial plexopathy in breast cancer patients Br J Cancer 79 3-4 1999 478 482
54. W.B. Eubank, D.A. Mankoff, J. Takasugi, H. Vesselle, J.F. Eary, and T.J. Shanley 18fluorodeoxyglucose positron emission tomography to detect mediastinal or internal mammary metastases in breast cancer J Clin Oncol 19 15 2001 3516 3523
55. A. Eltahir, S.D. Heys, A.W. Hutcheon, T.K. Sarkar, I. Smith, and L.G. Walker Treatment of large and locally advanced breast cancers using neoadjuvant chemotherapy Am J Surg 175 2 1998 127 132
56. R.L. Wahl, K. Zasadny, M. Helvie, G.D. Hutchins, B. Weber, and R. Cody Metabolic monitoring of breast cancer chemohormonotherapy using positron emission tomography: initial evaluation J Clin Oncol 11 11 1993 2101 2111
57. R. Tiling, R. Linke, M. Untch, A. Richter, S. Fieber, and K. Brinkbaumer 18F-FDG PET and 99mTc-sestamibi scintimammography for monitoring breast cancer response to neoadjuvant chemotherapy: a comparative study Eur J Nucl Med 28 6 2001 711 720
58. T. Jansson, J.E. Westlin, H. Ahlstrom, A. Lilja, B. Langstrom, and J. Bergh Positron emission tomography studies in patients with locally advanced and/or metastatic breast cancer: a method for early therapy evaluation? J Clin Oncol 13 6 1995 1470 1477
59. M. Schelling, N. Avril, J. Nahrig, W. Kuhn, W. Romer, and D. Sattler Positron emission tomography using [(18)F]fluorodeoxyglucose for monitoring primary chemotherapy in breast cancer J Clin Oncol 18 8 2000 1689 1695
60. I.C. Smith, A.E. Welch, A.W. Hutcheon, I.D. Miller, S. Payne, and F. Chilcott Positron emission tomography using [(18)F]-fluorodeoxy-D-glucose to predict the pathologic response of breast cancer to primary chemotherapy J Clin Oncol 18 8 2000 1676 1688
61. P. Bassa, E.E. Kim, T. Inoue, F.C. Wong, M. Korkmaz, and D.J. Yang Evaluation of preoperative chemotherapy using PET with fluorine-18- fluorodeoxyglucose in breast cancer J Nucl Med 37 9 1996 931 938
62. D.A. Mankoff, L.K. Dunnwald, J.R. Gralow, G.K. Ellis, A. Charlop, and T.J. Lawton Blood flow and metabolism in locally advanced breast cancer: relationship to response to therapy J Nucl Med 43 4 2002 500 509
63. D. Vranjesevic, J.E. Filmont, J. Meta, D.H. Silverman, M.E. Phelps, and J. Rao Whole-body (18)F-FDG PET and conventional imaging for predicting outcome in previously treated breast cancer patients J Nucl Med 43 3 2002 325 329
64. E.M. Kamel, M.T. Wyss, M.K. Fehr, G.K. von Schulthess, and G.W. Goerres [18F]-Fluorodeoxyglucose positron emission tomography in patients with suspected recurrence of breast cancer J Cancer Res Clin Oncol 129 3 2003 147 153
65. G.W. Goerres, S.C. Michel, M.K. Fehr, A.H. Kaim, H.C. Steinert, and B. Seifert Follow-up of women with breast cancer: comparison between MRI and FDG PET Eur Radiol 13 7 2003 1635 1644
66. T. Inoue, K. Yutani, T. Taguchi, Y. Tamaki, E. Shiba, and S. Noguchi Preoperative evaluation of prognosis in breast cancer patients by [(18)F]2-deoxy-2-fluoro-D-glucose-positron emission tomography J Cancer Res Clin Oncol 130 5 2004 273 278
67. D.M. Bruce, N.T. Evans, S.D. Heys, G. Needham, H. Ben Younes, and P. Mikecz Positron emission tomography: 2-deoxy-2-[18F]-fluoro-D-glucose uptake in locally advanced breast cancers Eur J Surg Oncol 21 3 1995 280 283
68. H. Palmedo, H. Bender, F. Grünwald, P. Mallmann, D. Krebs, and H. Biersack Comparison of fluorine-18 fluorodeoxyglucose positron emission tomography and technetium-99m methoxyisobutylisonitrile scintimammography in the detection of breast tumors Eur J Nucl Med 24 9 1997 1138 1145
69. A.Y. Rostom, J. Powe, A. Kandil, A. Ezzat, S. Bakheet, and F. el-Khwsky Positron emission tomography in breast cancer: a clinicopathological correlation of results Br J Radiol 72 863 1999 1064 1068
70. K. Yutani, E. Shiba, H. Kusuoka, M. Tatsumi, T. Uehara, and T. Taguchi Comparison of FDG-PET with MIBI-SPECT in the detection of breast cancer and axillary lymph node metastasis J Comput Assist Tomogr 24 2 2000 274 280
71. K.F. Hubner, G.T. Smith, J.A. Thie, J.L. Bell, H.S. Nelson, and W.T. Hanna The potential of F-18-FDG PET in breast cancer. Detection of primary lesions, axillary lymph node metastases, or distant metastases Clin Positron Imaging 3 5 2000 197 205
72. H. Bender, J. Kirst, H. Palmedo, A. Schomburg, U. Wagner, and J. Ruhlmann Value of 18-fluorodeoxyglucose positron emission tomography in the staging of recurrent breast carcinoma Anticancer Res 17 3B 1997 1687 1692
73. T.S. Kim, W.K. Moon, D.S. Lee, J.K. Chung, M.C. Lee, and Y.K. Youn Fluorodeoxyglucose positron emission tomography for detection of recurrent or metastatic breast cancer World J Surg 25 7 2001 829 834
74. W.Y. Lin, S.C. Tsai, K.Y. Cheng, R.F. Yen, and C.H. Kao Fluorine-18 FDG-PET in detecting local recurrence and distant metastases in breast cancer-Taiwanese experiences Cancer Invest 20 5-6 2002 725 729
75. M. Suarez, M.J. Perez-Castejon, A. Jimenez, M. Domper, G. Ruiz, and R. Montz Early diagnosis of recurrent breast cancer with FDG-PET in patients with progressive elevation of serum tumor markers Q J Nucl Med 46 2 2002 113 121
76. J. Dose, C. Bleckmann, S. Bachmann, K.H. Bohuslavizki, J. Berger, and L. Jenicke Comparison of fluorodeoxyglucose positron emission tomography and "conventional diagnostic procedures" for the detection of distant metastases in breast cancer patients Nucl Med Commun 23 9 2002 857 864